Advantage of Scheduled Upfront Lenvatinib Administration Followed by Transarterial Chemoembolization Therapy Over Lenvatinib Monotherapy in Patients With Unresectable Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Cohort Study.

ABSTRACT:

Background and aim

Combining systemic chemotherapy with transarterial chemoembolization (TACE) has demonstrated improved outcomes, with promising results for the efficacy of lenvatinib pretreatment combined with TACE in single-arm studies involving patients with hepatocellular carcinoma (HCC). This study aimed to evaluate the efficacy of a scheduled upfront lenvatinib combined with a TACE regimen in patients with HCC, representing both the first study to comparatively analyze this approach and to focus specifically on patients unsuitable for TACE.

Methods

We conducted a multicenter retrospective study between 2018 and 2024, enrolling 41 patients with unresectable Barcelona Clinic Liver Cancer intermediate-stage HCC who were considered unsuitable for TACE owing to factors suc

SUBMITTER: Taniki N 

PROVIDER: S-EPMC12811626 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature